View
2
Download
0
Category
Preview:
Citation preview
ESIC CENTRAL RATE CONTRACT NO. -142
FOR SUPPLY OF DRUGS & DRESSINGS
(VALID FROM 3rd MAY, 2018 to 2"d MAY, 2020)
DRUGS FOR GASTRO INTESTINAL SYSTEM DRUGS FOR MUSCULO-SKELETAL DISORDERS & TISSUE
INFLAMMATION DRUGS FOR EYE & ENT
STRICTLY FOR OFFICIAL USE
EMPLOYEES' STATE INSURANCE CORPORATION ROOM NO. 312 & 314, HQRS. OFFICE, PANCHDEEP BHAWAN
C.I.G. ROAD, NEW DELHI-110 002
ESIC CENTRAL RATE CONTRACT NO. -142
FOR SUPPLY OF DRUGS & DRESSINGS
(VALID FROM 3rd MAY, 2018 to 2nd MAY, 2020)
DRUGS FOR GASTRO INTESTINAL SYSTEM DRUGS FOR MUSCULO-SKELETAL DISORDERS & TISSUE
INFLAMMATION DRUGS FOR EYE & ENT
[ . STRICTLY FOR OFFICIAL USE
PUBLISHED BY
DIRECTOR GENERAL EMPLOYEES' STATE INSURANCE CORPORATION
ROOM NO. 312 & 314, HQRS. OFFICE, PANCHDEEP BHAWAN C.I.G. ROAD, NEW DELHI-110 002
Sno. Contents Page No.
1. Forwarding letter along with terms & I-XI conditions for operation of Rate Contract No. 139 (A).
r
2. List of Approved Pharmaceutical firms. 1
3. Address with Terms & Conditions of the 1-5 Eligible firms
4. Index 1-2
5. Rate Schedule 1-13
REGISTERED STRICTLY FOR OFFICIAL USE ONLY
HQRS. OFFICE EMPLOYEES' STATE INSURANCE CORPORATION
PANCHDEEP BHA WAN: C.I.G. ROAD: NEW DELHI -110 002 TeiFax: 011-23234334, E-mail: dmc-rc.esic@nic.in, dmc.rc.esic@qmail,com
(An IS0-9001 :2008 Certified)
No.U-25/12/142/2017-Med. V/RC 142 Dated: 3'a May, 2018
From:
To
The Director General, E.S.I. Corporation, Panchdeep Bhawan, C.I.G Road, NEW DELHI - 110 002.
The Director, ESI Scheme- All States Medical Superintendent- ESIC Model Hospitals
Sub PURCHASE OF DRUGS AND DRESSINGS UNDER THE E.S.I. CORPORATION CENTRALISED RATE CONTRACT NO. 142 EFFECTIVE FROM 03.05.2018 TO 02.05.2020.
Sir I Madam,
Please find enclosed a copy of the DG-ESIC Centralised Rate Contract finalised for supply of drugs and dressings under the ESI Scheme in the country. The rate contract will come into force with effect from the date of issue of this rate schedule, i.e, 03.05.2018. Further, the following instructions are issued to govern operation of the Rate Contract.
1. Immediately on receipt of this communication, the Chief Direct Demanding Officers (Director/Add!. Director/Jt. Director/Dy. Director/Administrative Medical Officer/Director (Medical) Delhi shall intimate the names and complete address of the officers who have been designated as Direct Demanding Officer for the purpose of operation of this Rate Contract on his behalf, to all the Rate Contract holders. The Rate Contract holders would entertain the supply orders & related correspondences from the officers working as DDOs only after the receipt of such communication from the Chief DDOs.
I
2. The Chief DDOs may bring to the notice of the undersigned the discrepancies (especially in rate, packing, composition of the drug) if any observed by them. In case the rates of the firms approved in this Rate Contract are found to be higher than their rates in any local Rate Contract or in the market, the same may be intimated along with the documentary proof.
3. The applicability of GST may affect to some extent the rates finally approved under this Rate Contract and in such cases, orders may be placed to the firm at the lowest rates. While taking this step, the benefit of concession in rate of GST available under GST Act or the rules framed there under will be taken into account.
4. The Stores accepted should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder as amended upto date and Drug Price Control Order.
SUPPLIES
5. All the supply orders shall be signed only by the officers who have been duly authorised and included in the list of DDOs. DDOs will send scanned copy of the Purchase order through email followed by Registered AD post directly to the firm alongwith a copy to the office of the firm situated at the respective zone.
6. It will be ensured before placing order by the Director Demanding Officer that necessary funds are available and payment of bills should be arranged expeditiously within 4-6 weeks time of the execution of the orders by the Rate Contract Holder and there should not be unnecessary delay in the payment of their bills.
7. Supply orders will be placed from time to time during the currency of the contract in which the exact quantities required on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers.
8. Supply orders will be placed by Heads of ESI Scheme of various States/ Medical Superintendents, ESIC Model Hospitals, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director General, ESI Corporation in all matters connected with the execution of supplies and I or wherever specifically provided in the terms & conditions of the Rate Contract. The
II
Chief Direct Demanding Officer can also designate any of his subordinate officer as Direct Demanding Officer (DDO) to operate this Rate Contract
9. Supply orders against the contract will be accepted as long as these reach the contractor on or before last date of the currency of the contract. Supply orders received during the closing days should be complied within due course, in accordance with the contract if even though in some cases owing to contract having expired, supplies are to be complied with even after the expiry of the last date of the contract.
10. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the contractor I seller to supply the item as per the specifications of the relevant rate contract.
11. During transit pharmaceutical firm should maintain the recommended temperature of the drug (wherever indicated), otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled. It will be counted as a non-supply.
12. in all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the public/open market.
13. The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance, Octroi etc, if any, will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the contractor of any loss or damage to the stores, that may have occurred during the transit.
14. Marking : Each packing shall be printed with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under. Packing & packaging of the each drug must comply with the procedure provided under the Legal Metrology Act, 2009 and rules made there under.
III
15. Packing : a) It should be ensured that all labels of cartons, ampoules, vials,
bottles, jars, tubes, tins, containers etc., have "For ESI supply, Not to be sold" imprinted clearly. Any consignment without such stamping will not be considered valid and will be rejected.
b) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be accepted under any circumstances.
c) Supplies to be made in proper boxes. d) Liquid orals to be supplied only in glass/ plastic bottles conforming to
IP I Drugs & Cosmetics Act. e) Large volume parenterals to be quoted and supplied only in plastic
bottles I polypacks conforming to I.P. f) It should be ensured that only first use packaging material of
uniform size including Bottles and vials should be used for making supplies on the basis of ESI Rate Contract.
g) All primary packing containers should be strictly conforming to the specifications described/ mentioned in the relevant pharmacopoeia.
h) Packing should be able to prevent damage or deterioration during transit.
i) All containers i.e. bottles, tins, cartons, tubes etc., are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents.
j) It should be ensured that lSI Code No. is indicated on the packing and at the time of supplies, it must be ensured that the items supplied has lSI Mark as well as Code No., as is the statutory requirement of the Bureau of Indian Standards.
16. Life Period : a) For Drugs having shelf life of Two years or less: Drug supplied
should not be older than one fourth (1/4) of its shelf life from the date of manufacture.
b) For Drugs having shelf life more than Two years: Drug supplied should not be older than one sixth (1/6) of its shelf life from the date of manufacture.
c) For Imported Drugs: All Imported Drugs should have 50 % of shelf life from the date of manufacture at the time of supply.
17. Pharmacopoeia Specifications : Pharmacopoeia Specification IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the drug supplied as per the provisions of Drug and Cosmetics Act.
IV
18. Testing of Drugs - Quality Control a) Approved Rate Contract Holder should submit a Test Report
that particular batch of medicines tested by the Government! Government approved Laboratories (as per list circulated from ESIC Hqrs/ Hospitals/ State Govt. from time to time) along with each supply.
b) The Chief D.D.Os may get at least 10% of the drugs tested in the Government Laboratory, or in any of the Govt. Approved laboratories, the list of which has been issued. Instructions issued in this regard Hqrs. Office from time to time may please be adhered to Details of the items found not of standard quality should be brought to the notice of the undersigned along with the test reports immediately. All such test reports should necessarily come through Chief D.D.Os only. A copy of the test report should be sent immediately to the firm, the concerned Drug controllers, and respective Central Drug Control authorities for necessary action.
c) Regular and random testing of drugs will be under taken by ESI from Govt./Govt. approved laboratories at the time of supply and at any time during the shelf life or whenever any defect is noticed. The Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the pharmaceutical firm/ firm at regular interval to maintain and ensure the quality of drugs.
d) The report of the Govt./Govt. approved laboratory shall be accepted by the pharmaceutical firm. In case the same is disputed by the pharmaceutical firm the report of the Appellate Laboratory only will be accepted as final. However the same should be submitted within three months, from the date of communication of the disputed test report to the pharmaceutical firm. For this, the pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure, from the Appellate Laboratory.
e) If any store/stores supplied against this Rate Contract are found to be Not of standard quality on test analysis from approved laboratory and I or on inspection by competent authority, the contractor will be liable to replace the entire quantity or make full payment of entire consignment against the
v
particular invoice irrespective of fact that part or whole of the supplied stores may have been consumed.
f) If the product is found to be 'not of standard quality', the cost of testing will be recovered from the supplier.
The classification of defects into diff~rent categories is as per the guidelines issued by the Drug Controller of India & action will be taken by ESIC for each category of defects, described as under:-
A. CATEGORY 'A' DEFECT (Spurious I Adulterated Drugs)-lf any item I Batch of the item declared Not of Standard quality (NSQ) under Category A . • Recall of the NSQ item immediately from all ESIC/ ESIS User
Units. Recoveries to be initiated by the DDO's wherever payment had been made already.
• Forfeiture of Performance Security from the respective DGESIC Rate Contract.
• Debarring of the Rate Contract holder I Pharmaceutical firm from current and all future DGESIC Rate Contract for a period of five (5) years.
• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drug.
B. CATEGORY 'B' DEFECT (Grossly Substandard Drugs) I. If single item/ Batch of item is declared NSQ under Category B
• Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already.
• Forfeiture of Performance Security from the respective DGESIC Rate Contract.
• Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract.
• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of
VI
any adverse reaction reported in the Hospital during administration of the drugs.
II. If more than one item/ Batch of item belonging to any individual pharmaceutical firm is declared NSQ under Category B within a year • Recall of the NSQ item immediately from all ESIC/ ESIS User
Units. Recoveries to be initiated by the DDO's wherever payment had been made already.
• Forfeiture of Performance Security from the respective DGESIC Rate Contract.
• Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract.
• Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for a period of three years.
• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.
C CATEGORY' C' DEFECT (Minor Defects) I. If single item/ Batch of item is declared NSQ under Category C
• Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already.
• Forfeiture of Performance Security from the respective DGESIC Rate Contract.
• Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract.
• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.
VII
II. If more than one item/ Batch of item belonging to any individual pharmaceutical firm is declared NSQ under Category C within a year
• Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already.
• Forfeiture of Performance Security from the respective DGESIC Rate Contract.
• Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract.
• Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for a period of three years
• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.
19. Delivery Period - Risk Purchase a. Delivery period will be six weeks. b. If the pharmaceutical firm fails to execute the supply order within
the stipulated period of six weeks, a penalty of two (2) per cent of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 1 0% of the total value of the order/orders. A pharmaceutical firm can seek extension of the delivery period with the prior consent of the Director Demanding Officers, if it is not in a position to execute the order in time. Such extension is permissible for a maximum period of 5 weeks only but penalty will be levied. That extension of deliverv period cannot be claimed as a matter of right but will be at the discretion of concerned Officer.
c. If the items/ drugs are not supplied by the schedule date (as indicated above or by the extended date) full or in part, the order in respect of the quantity not supplied is liable to be cancelled at the risk and expense of pharmaceutical firm. The extra expenditure involved in procuring supplies from elsewhere will, in that case, be recoverable from the
VIII
pharmaceutical firm, in full at discretion of Direct Demanding Officers. The recoveries thus due will be deducted from any sum payable by the Direct Demanding Officer or which at any time thereafter may become payable under this contract or any other contract placed with firm by the Direct Demanding Officers. He will be deemed to be exercising the powers of Director General, ESI Corporation in case any such contingency arises. Apart from risk purchase action, the firm's the Performance security deposit may be forfeited and shall invite other penal action like debarring from participating in ESI Corporation Rate Contract present and future for a period of not less than five years.
d. In case of failure to supply, the Corporation reserves the right to purchase the stocks from other sources as risk purchase, i.e. purchase from any other pharmaceutical firm or firms, in the rate contract or from outside the contract at the discretion of the Direct Demanding Officer concerned at a competitive rate.
20. Payment a. Payment may be made directly to the firm. Payment for the supply will
be made within 4 to 6 weeks (after receipt and acceptance of the drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills are submitted. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the pharmaceutical firm to supply the items as per the specifications of the relevant rate contract
b. The price charged for the stores supplied under the agreement or the rate quoted by firm for supply of medicines to the DG-ESIC, whichever is lower, shall in no event exceed the lowest price at which the firm sells the stores of identical description to any other person(s) during the said period of agreement. If at any time during the said period, the firm reduces the sales price of such stores or sells such stores to any other person at a price lower than the price chargeable under the agreement, he shall forthwith notify such reduction in sale price to the Director General, E.S.I. Corporation and Direct Demanding Officers and the price payable under the agreement for the stores supplied after the date of its coming in to force will be the reduced price. The approved price in Rate Contract shall stand correspondingly reduced. The preference in the Rate contract will not be changed till any further fresh instructions.
IX
c. The price must be quoted F.O.R Destination per unit as shown in the schedule annexed and should be exclusive of GST Tax but inclusive of all charges for packing and forwarding.
d. GST Taxes, if extra, where legally leviable and intended to be claimed, should be distinctly shown separately alongwith the price quoted. Where this is not done, no claim of GST taxes will be admitted at any later stage and on any ground whatsoever.
e. The purchaser will not pay separately for transit insurance and the firm will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance,octroi etc., if any, will have to be borne by the firm.
f. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the pharmaceutical firm, of any loss damage to the stores, that may have occurred during the transit.
21. Any dues or payments that have arisen to the Corporation from the contractor for which no specific time limit has been laid down in the terms and conditions shall be payable by the contractor within such time limit as may be prescribed in the letters I orders addressed to the contracts.
22. Any payments that have been demanded as per the provision of Clause 22 or under any other clause shall be payable within the time laid down. On failure to do so: -1. The Contractor shall be liable to be debarred for supplying
medicines I drugs etc. to the Corporation for a period not exceeding five years.
ii. The contract is liable to be prosecuted in the court of law. 23. Non Supply
The Chief DDOs shall monitor the performance of the Rate Contract holding firms in regard to their execution of supply orders in time. He shall send a consolidated quarterly non-supply report (in Excel format only) along with the comments and details as under:-
PROFORMA FOR NON-SUPPLY REPORT R.C. Item No. & Name of S.O.No. Qty. not Risk Payment Remarks No. Name of firm with supplied Purchase/ if
Drug Date penalty pending levied
1. 2. 3. 4. 5. 6. 7. 8.
X
24. Rate Schedule along with list of item-wise finalized rates, along with name of the approved firms is enclosed. In regard to items where rates of more than one firm have been approved, order should be placed to the firm at First Preference and whose rates are the lowest. In case of non-supply by such firm, order shall be placed to the firm with the next higher approved rate invoking risk purchase.
25. No other document should be entertained for giving any cognizance for placing the supply orders.
26. Acceptance letter issued to the firms by this office cannot be used for placing orders.
Receipt of this letter may please be acknowledged.
Encl.: As above.
Copy to:
Yours faithfully,
(Dr.~ Logani) Dy. Medical Commissioner (RC)
For: DIRECTOR GENERAL
1. All Chief Direct Demanding Officers (In-Charge) of ESI Scheme of all States for information and with the request to circulate this letter along with enclosures among all DDOs under their control for necessary compliance. They are also requested to send the list of DDOs to the firms approved in the Rate Contract.
2. P.S. to Director General for information of Director General. 3. Medical Commissioner I Financial Commissioner for information. 4. Accounts Branch- V (Hqrs. Office) 5. SSMC I SMC (All States)
DY. MEDI~~MISSIONER (RC)
XI
Approved Vendor list
SNO. FIRM NAME
1 ABBOTT HEALTHCARE PRIVATE LIMITED
2 ABBOTT INDIA LIMITED
3 AJANTA PJ-IARMA L TO,,
4 ALCON LABORATORIES (INDIA) PRIVATE LIMITED
5 BAYER ZYDUS PJ-IARMA PRIVATE LIMITED
6 C/PLA LTD
7 CORONA REMEDIES PVT LTD
8 EMCURE PHARMACEUTICALS LIMITED
9 GLAXOSMITHKLINE PHARMACEUTICALS LTD
10 GLEN MARK PHARMACEUTICALS LIMITED
11 JOHNSON & JOHNSON PRIVATE LIMITED
12 MICRO LABS LTD
13 OVERSEAS HEALTH CARE PVT LTD
14 PSYCHOTROPICS INDIA LIMITED
15 SANOFIINDIA LIMITED
16 TABLETS (INDIA} LIMITED
17 TORRENT PHARMACEUTICALS LTD
18 TROIKAA PHARMACEUTICALS LIMITED
19 USV PRIVATE LIMITED
20 WALLACE PHARMACEUTICALS PVT LTD
Page 1 of 1
Vendor Name
Abbott Healthcare Private limited
Floor 17, Godrej BKC, Plot No. C-68, BKC, Near MCA Club, Bandra (E), Mumbai-400051 Maharashtra
Tel: 022-2238160527, 7777020398
Term 1
Term 2
Term 3
Term4
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Email: institution.business@abbott.com & imran.dar@abbott.com
Vendor Name
Abbott India Limited
Floor 16, Godrej BKC, Plot No. C-68, BKC, Near MCA Club, Bandra (E), Mumbai-400051 Maharashtra
Tel: 022-2238160527, 7777020398
Term 1
Term 2
Term 3
Term4
Delivery within 6(six) weeks (of the actual date of
dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Email: institution.business@abbott.com & imran.dar@abbott.com
Vendor Name
Ajanta Pharma Ltd.,
Ajanta House 98 Govt. Industrial Estate Charkop Kandivali West Mumbai Maharashtra- 400067
Tel: 022-66061202, 66061221, 66061200,66061300
Email: dilip.bagdiya@ajantapharma.com
Vendor Name
ALCON LABORATORIES {INDIA) PRIVATE LIMITED 3rd Floor, Crescent 4, Prestige Shantiniketan, Whitefield BANGALORE-560048,KARNATAKA
Tel: 8040064600, 9008528787
Email: Palav.Sahadev@Novartis.com
Term 1
Term 2
Term 3
Term4
Term 1
Term 2
Term 3
Term 4
Page 1 ofS
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis
GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis
GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Vendor Name
Bayer Zydus Pharma Private Limited 5th Floor, Bayer House, Central Avenue, Hiranandani Estate, Thane(W)-400607
Tel: 2225311710, 2225455078 9819358800
Term 1
Term 2
Term 3
Term4
Email: chetan.nashirkar@bayerzyduspharma.com
Vendor Name
Cipla Ltd
Cipla Limited, Mumbai Central, Mumbai-400008 Maharastra
Tel: 8879967909
Email: manojkumar.singh@cipla.com
Vendor Name
Corona Remedies Pvt ltd
Corona House, C- Mandel Business Park Near Gurudwara S.G. Highway, Thaltej Ahmedabad Gujarat-380059
Tel: 079 40233000/65426663
Email: harishs@coronaremedies.com
Vendor Name
Emcure Pharmaceuticals Limited
Emcure House Plot No. 184, MIDC Bhosari Pune- 411026 Maharashtra
Tel: 2039192761
Email: nitin.nagar@emcure.co.in
Term 1
Term 2
Term 3
Term4
Term 1
Term 2
Term 3
Term 4
Term 1
Term 2
Term 3
Term 4
Page 2 ofS
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis
GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled. Supply to be made directly.
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis
GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Delivery within 6(six) weeks (ofthe actual date of dispatch) of supply order on FOR Destination basis
GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis
GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Vendor Name
GlaxoSmithKiine Pharmaceuticals Ltd GSK House, Dr.Annie Besant Road, Worli Mumbai-400030 Maharashtra
Tel: 022-24959249, 022-24959494, 9920898316
Term 1
Term 2
Term 3
Term4
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis
GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Email: sunil.m.tawde@gsk.com & pankaj.x.popli@gsk.com
Vendor Name
GLEN MARK PHARMACEUTICALS LIMITED GLEN MARK HOUSE, B D SA WANT MARG, Chakala, ANDHERI (EAST) MUMBAI MAHARASHTRA-400099
Tel: 22-40888925/927, 22-40189988, 09324291478
Term 1
Term 2
Term 3
Term 4
Email: shantaram.patil2@glenmarkpharma.com
Vendor Name
Johnson & Johnson Private Limited
8th Floor, ARENA SPACE OFF JVLR BEHIND MAJAS DEPOT, JOGESHWARI EAST MUMBAI MAHARASHTRA-400060
Tel: 22 61087103, 022 66718200, 09892101039
Email: sshind15@its.jnj.com
Vendor Name
MICRO LABS LTD
No. 27, RACE COURSE ROAD, BANGALORE KARNATAKA 560001
Tel: 080-22256323, 22370463
Term 1
Term 2
Term 3
Term4
Term 1
Term 2
Term 3
Term4
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis
GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled. Supply to be made directly.
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled. Supply to be made directly.
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis
GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Email: rakeshsharma_micro@yahoo.co.in & shankars@microlabs.in
Page 3 of5
Vendor Name
OVERSEAS HEALTH CARE PVT LTD
335 KM MILESTONE, NH N0.1, P.O.BOX-25 PHILLAUR- 144410 PUNJAB
Tel: 01826-222886, 01826-222885, 9872019733
Email: info@overseashealthcare.co.in
Vendor Name
PSVCHOTROPICS INDIA LIMITED
PLOT NO. 17 SECTOR- 20 A, FARIDABAD- 121001 FARIDABAD HARYANA Tel: 0129-2296764
Email: kapoorsatish72@yahoo.com
Vendor Name
Sanofi India Limited
Sanofi House, CTS No.117-B, L&T, Business Park, Saki Vihar Road, Powai, Mumbai- 110072
Tel: 022-28032000, 28032939
Email: institution.business@sanofi.com
Vendor Name
TABLETS (INDIA) LIMITED
Jhaver Centre, IV Floor, Raja Annamalai Building, 72, Marshalls Road, Egmore, Chennai-600008
Tel: 044-42050000, 28589090, 9380106636
Email: hd@tabletsindia.com
Term 1
Term 2
Term 3
Term 4
Term 1
Term 2
Term 3
Term4
Term 1
Term 2
Term 3
Term 4
Term 1
Term 2
Term 3
Term4
Page 4 ofS
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis
GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled. Supply to be made directly.
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis
GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Vendor Name
TORRENT PHARMACEUTICALS LTD
TORRENT HOUSE, OFF ASHRAM ROAD AHMEDABAD GUJARAT 380009
Tel: 079 26585090 I 3060
Term 1
Term 2
Term 3
Term4
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Email: atulshah@torrentpharma.com & vikrampatel@torrentpharma.com
Vendor Name
TROIKAA PHARMACEUTICALS LIMITED Commerce House- 1, Satya Marg, Bodakdev, Ahmedabad-380054 Gujarat
Tel: 079-26856242 I 43 I 45 I 46, 9879615617
Email: institution@troikaapharma.com
Vendor Name
USV Private Limited
Arvind Vithhal Gandhi Chowk, B.S.D Marg, Govandi, Mumbai- 400088 Maharashtra
Tel: 022-25564048
Email: manoj.sharma@usv.in
Vendor Name
WALLACE PHARMACEUTICALS PVT LTD
B 307-312 FLORAL DECK, PLAZA. OFF CENTRAL MIDC ROAD, ANDHERI (EAST), MUMBAI MAHARASHTRA 400093
Tel: 022-29261152, 022-28390733, 9820360019
Term 1
Term 2
Term 3
Term 4
Term 1
Term 2
Term 3
Term 4
Term 1
Term 2
Term 3
Term 4
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis
GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis
GST as applicable will be extra except for items where no tax has been approved.
If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.
Supply to be made directly.
Email: ms379@hotmail.com & pravinwani@wallacepharma.net
Page 5 of 5
----·· - -----·---~-~-~----- .. ---RC 142 (Index) ----
Item
Sno. No. Item Name and Description Unit Page No.
RABEPRAZOLE SODIUM 20mg + MOSAPRIDE CITRATE lSmg sustained release
1 1496 CAP 1 cap. 1
LANSOPRAZOLE 1SMG TAB/CAP- Each orally disintegrated Tab /cap to
2 2009 contain: Lansoprazole 15mg (as Enteric Coated pellets) 1 Tab/Cap 1
2053 Rabeprazole Sodium IP 20 mg (as enteric coated pellets) Domperidone IP 30
3 mg (as sustained release pelletes) Tab 1 cap. 1
4 1822 LACTULOSE SYP - Each 15m I to contain : Lactulose 10gm
200ml bot 2
5 1823 LACTULOSE SYP- Each 15m I to contain : Lactulose 10gm 450ml bot 2
ANTISPASMODIC DROPS/SUSPENSION - Each mi. to contain: Dicyclomine Hcl
6 16 10 mg, Activated Dimethicone 40mg. 10 mi. Bot. 2
DICYCLOMINE +MEFENAMIC TAB- Each Tab to contain: Dicyclomine lOmg.,
7 1346 Mefenamic Acid 250mg. 1 Tab 3
8 2056 Chlordiazepoxide Smg, Clidinium Bromide 2.5mg Tab 1 tab 3
LIVER DISORDERS SYP • Each 15m I contains: DL-Methionine BP 100mg,
Choline Dihydrogen Citrate NFX11100mg, L·Leucine USP 19mg, L-lsoleucine
USP 10mg ,L-Valine USP11mg, Pyridoxine HciiP l.Smg, Nicotinamide IP
22.5mg, Biotin USP 0.1mg, Folic Acid IP 0.5 mg, Cyanocobalamin IP 3.0 meg,
9 1991 Inositol BP SOmg 200ml bot 3
LIVER DISORDERS TAB- Each tab to contain: DL-Methionine BP 200mg,
Choline Bitartrate (as coated) USP 200mg, L-Leucine USP 19mg, L-lsoleucine
USP 10mg, L-Valine USP 11mg, Pyridoxine Hydrochloride IP
l.Smg,Nicotinamide IP 22.5mg, Biotin USP 0.1mg, Folic Acid IP 0.5 mg,
10 1992 Cyanocobalamin IP 3.0 meg, Inositol BP 50 mg 1 tab 4
11 577 URSODESOXYCHOLIC ACID 150mg TAB 1 tab 4
12 2057 Ursodoxycholic Acid 300mg Tab 1 tab 5
13 2058 Pancreatin 170mg Activated Dimethicone 80mg tab 1 tab 5
HAEMORRHOIDAL CREAM- Containing: Beclomethasone dipropionate 0.025 20gm
14 358 %, Phenylepherine Hydrochloride 0.1 %, Lignocaine hydrochloride 2.5 %. Tube 5
1856 TRAMADOL AND PARACETAMOL TAB/ CAP- Each tab/cap to
15 contain:Tramadol 37.50 mg, Paracetamol325mg 1 tab/ cap 6
1093 IBUPROFEN AND PCM ORAL SUSP- Each 5 ml to contain: Ibuprofen 100 mg.,
16 Paracetamol162.5 mg. 60ml bot 6
17 1376 HYDROXY CHLOROQUINE 200mg TAB 1 tab 7
18 1675 LORNOXICAM SR 16mg TAB 1 tab 7
Page 1 of 2
~---- ----~--·~--- --
RC 142 (Index) --
Item
Sno. No. Item Name and Description Unit Page No.
19 1862 FEBUXOSTAT TAB- Each tab to contain: Febuxostat 40mg 1 tab 8
20 2024 PARACETAMOL 650MG TAB 1 tab 8
21 2082 Dexketoprofen 25mg + Paracetamol 325mg Tab ltab 8
Aflibercept injection 40 mg I miAflibercept (r-DNA Origin) solution for
intravitreal injection in Via lEach pack contains: 1 vial and a 18 G Sterile filter
needle 278 microliters/vial Each single dose vial provides a usable amount to
22 2083 deliver a single dose of 50 microliters containing 2mg Aflibercept 1 vial 9
ANALGESIC CREAM : Methyl salicylate 30% w/w, Menthol10% w/w,
23 1866 Camphor 4% w/w Excipients q.s. 30 gm tube 9
24 1432 OLOPATADIN EYE DROP- Each vial: Olopatadin l.Omg
5mlvial 9
DORZOLAMIDE+TIMOLOL EYE DROP- Each vial to contain: Dorzolamide 2% 1601
,Timoloii.P. 0.5% 25 5mlvial 10
CARBOXY METHYL CELLULOSE EYE DROP- Each ml to contain: Sodium 1923
Carboxy methyl cellulose Smg 26 10m I vial 10 - - --27 1924 DORZOLAMIDE EYE DROP- Each vial: Dorzolamide 2% 5mlvial 10
28 1228 ACYCLOVIR EYE OINT- Each tube to contain: Acyclovir I.P.3% Sgm tube 11
MOXIFLOXACIN +PREDNISOLONE EYE DROP- Each vial to contain:
29 1598 Moxifloxacin 0.5%, Prednisolone Acetate 1%, 5mlvial 11
f-- 30 1599 MOXIFLOXACIN EYE OINT- Each tube : Moxifloxacin 0.5% Sgm tube 11
BESIFLOXACIN EYE DROP- Each ml to contain: Besifloxacin 0.6% {6mg/ml),
Excepients: Polycarbophil, Mannitol, Poloxamer 407, Sodium Chloride,
31 1912 Edetate Disodium Dihydrate, Sodium Hydroxide and water for injection 5ml bottle 11
32 1602 TRAVOPROST EYE DROP- Each vial: Travoprost 0.004% 2.5ml 12
1925 TRAVOPROST AND TIMOLOL EYE DROP- Each vial to contain: Travoprost
33 0.004%, Timolol 0.5% 2.5ml vial 12
ANTIBIOTIC EYE OINTMENT- Each gram to contain:Polymyxin B Sulphate
5000 IU Neomycin sulphate 3400 IU Zinc Bacitracin 400 IU Hydrocortisone 10
34 1211 mg. 5gm. Tube 13
POLYMIXIN, NEOMYCIN EYE OINT.- containing per gm. Polymixin B Sulphate
35 1251 5000 IU Neomycin sulphate 3400 IU Zinc Bacitracin 400 IU 5gm. Tube 13
36 1212 FLURBIPROFEN EYE DROPS- Containing: Flurbiprofen 0.03% w/v 5ml. Vial 13
37 1594 EYE DROPS -Containing: Gatifloxacin Soln 0.3% w/v 5mlvial 13
Page 2 of 2
Employees' State Insurance Corporation
Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 142
Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020
lttem No I Drug Description
Firm Name Firm Rate/ unit Firm Packing Preference
1496 RABEPRAZOLE SODIUM+ MOSAPRIDE CITRATE CAP - Cap, Rabeprazole sodium 20mg, Mosapride Citrate 15mg sustained release
TORRENT 2.82/1 cap. 10Cap FIRST PHARMACEUTICALS LTD
Rupees two paisa eighty two only
I Packing
Description of stores accepted
1 cap.
Rabeprazole sodium IP 20 mg (as enteric coated pellets) VELOZ M SAME AS IN ITEM
12009 LANSOPRAZOLE 15MG TAB/CAP- Each orally disintegrated Tab 1 Tab/Cap /cap to contain: lansoprazole 15mg (as Enteric Coated pellets)
Cipla Ltd 4.2667/1 15 tab FIRST JUNIOR LANZOL 15MG Tab/Cap
Rupees four paisa two six six seven only
2053 Each Hard gelatin capsule contains: Rabeprazole Sodium IP 20 mg (as enteric coated pell!!ts) Domperidone IP 36 mg (as sustained release pelletes)
Corona Remedies Pvt 0.89/1 cap. Ltd
10Cap FIRST
Rupees zero paisa eighty nine only
SAME AS IN ITEM
1 cap.
MACRO
SAME AS IN ITEM
USV PRIVATE LIMITED
1.16/1 cap. 10tab SECOND Drego D
MICRO LABS LTD 1.65/1 cap.
Rupees one paisa sixteen only
10 cap THIRD
Rupees one paisa sixty five only
Page 1 of13
SAME AS IN ITEM
RABIROS-D SAME AS IN ITEM
I
Employees' State Insurance Corporation
Rate Schedule of Running Rate Contract No. U-25/1Z/14Z/Z017-Med V FOR RC 14Z
Valid from Thursday May 3'd 2018 to Saturday May z"d ZOZO
/Item No I Drug Description I Packing
Firm Name Firm Rate/ unit Firm Packing Preference Description of stores
I 1822 I LACTULOSE SYP- Each 15ml to contain : Lactulose lOgm
Abbott India Limited 70/ZOOml bot ZOO ml bott FIRST
Rupees seventy only
accepted
I 200ml bot
DUPHALAC SAME AS IN ITEM
OVERSEAS HEALTH 87 .35/ZOOml ZOO ml bott SECOND LAXDAY SYRUP CARE PVT LTD bot
PSYCHOTROPIC$ INDIA LIMITED
Rupees eighty seven paisa thirty five only
88.44/ZOOml bot
200ml bott THIRD
Rupees eighty eight paisa forty four only
/1823 I LACTULOSE SYP- Each 15ml to contain : Lactulose 10gm .
Abbott India Limited 150/450ml bot 450ml bott FIRST
Rupees one hundred fifty only
SAME AS IN ITEM
Lactopil
SAME AS IN ITEM
I 450ml bot
OUPHALAC SAME AS IN ITEM
PSYCHOTROPIC$ 192.88/450ml 4SOmlbott SECOND Lactopil INDIA LIMITED bot
SAME AS IN ITEM
Rupees one hundred ninety two paisa eighty eight only
16 ANTISPASMODIC DROPS/SUSPENSION - Each mi. to contain: 10 mi. Bot. Dicyclomine HellO mg, Activated Dimethicone 40mg.
PSYCHOTROPIC$ 10.46/10 mi. 10 ML bott FIRST Spaskid drop INDIA LIMITED Bot.
SAME AS IN ITEM
Rupees ten paisa forty six only
Page 2 of13
Employees' State Insurance Corporation
Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 142
Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020
litem No I Drug Description I Packing
Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted
1346 DICYCLOMINE + MEFENAMIC TAB - Each Tab to contain: 1 Tab Dicyclomine 10mg., Mefenamic Acid 250mg.
PSYCHOTROPICS 0.45/1 Tab 10 tab FIRST Kolispas INDIA LIMITED
SAME AS IN ITEM
Rupees zero paisa forty five only
2056 Each tablet to contain Chlordiazepoxide Smg, Clidinium 1 tab Bromide 2.5mg
OVERSEAS HEALTH 2.56/1 tab 10 x 10tab FIRST SPASRAX CARE PVTLTD
SAME AS IN ITEM
Rupees two paisa fifty six only
Abbott Healthcare Private Limited
3.01/1 tab 10tab SECOND LIBRAX
Rupees three paisa one only
1991 LIVER DISORDERS SYP - Each l.Sml contains: DL-Methionine BP 100mg, Choline Dihydrogen Citrate NFXII 100mg, L-Leucine USP 19mg, L-lsoleucine USP 10mg ,L-Valine USP11mg ' Pyridoxine Hcl IP 1.5rng, Nicotinamide IP 22.Smg, Biotin USP O.lmg , Folic Acid IP 0.5 mg, Cyanocobalamin IP 3.0 meg, Inositol BP SOmg
TABLETS {INDIA} LIMITED
68.11/200ml bot
200ml bott FIRST
Rupees sixty eight paisa eleven only
Page 3 of13
SAME AS IN ITEM
200m! bot
NEUTROSEC LIQUID
SAME AS IN ITEM
Employees' State Insurance Corporation
Rate Schedule of Running Rate Contract No. U-25/12/142/::1.017-Med V FOR RC 142
Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020
litem No [ Drug Description
Firm Name Firm Rate/ unit Firm Packing Preference
1992 LIVER DISORDERS TAB- Each tab to contain: DL-Methionine BP 200mg , Choline Bitartrate (as coated) USP 200mg, L-Leucine USP 19mg, L-lsoleucine USP lOmg, L-Valine USP llmg, Pyridoxine Hydrochloride IP l.Smg,Nicotinamide IP 22.5mg, Biotin USP 0.1mg, Acid IP 0.5 mg, Cyanocobalamin IP 3.0 meg, Inositol BP 50 mg
TABLETS (INDIA) LIMITED
4.88/1 tab 10tab FIRST
Rupees four paisa eighty eight only
1
577 j URSODESOXYCHOLIC ACID TAB - Each Ursodesoxycholic acid 150mg.
tab. to contain:
PSYCHOTROPICS 6.13/1 tab 10 tab FIRST INDIA LIMITED
Rupees she paisa thirteen only
[Packing
Description of stores accepted
1 tab
NEUTROSEC
SAME AS IN ITEM
1 tab
Ursopil150
SAME AS IN ITEM
Corona Remedies Pvt 7.87/1 tab Ltd
lOtab SECOND URSOBILE 150
Rupees seven paisa eighty seven only
Abbott India Limited 7.96/1 tab 10 tab THIRD
Rupees seven paisa ninety six only
Page 4 of13
SAME AS IN ITEM
UDILIV 150 SAME AS IN ITEM
Employees' State Insurance Corporation
Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 142
Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020
Llt~re=m~N~o ______________ _Lio~r~u~g~D~e~sc~nLp~ti~on~ _______________ ILP~a~c~W_n_~g ___________ ]
Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted
I 2057 I Each tab to contains: Ursodoxycholic Acid 300mg 11 tab
PSYCHOTROPIC$ 11.9/1 tab 15 tab FIRST Ursopil300 INDIA LIMITED
SAME AS IN ITEM
Rupees eleven paisa ninety only
Abbott India Limited 15.15/1 tab 15 tab SECOND UDILIV 300 SAME AS IN ITEM
Rupees fifteen paisa fifteen only
Corona Remedies Pvt 15.39/1 tab Ltd
10tab THIRD
Rupees fifteen paisa thirty nine only
URSOBILE 300
SAME AS IN ITEM
2058 Each enteric coated tablet contains: Pancreatin 170mg 1 tab Activated Dlmethicone 80mg
Abbott India Limited 6.77/1 tab 15 tab FIRST PANKREOFLAT
358
USV PRIVATE LIMITED
Rupees six paisa seventy seven only
HAEMORRHOIDAL CREAM - containing: Beclomethasone diproplonate 0.025 %, Phenylepherine Hydrochloride 0.1 %, Lignocaine hydrochloride 25 %.
29.6/20gm Tube
20gmtube FIRST
Rupees:twenty nine paisa sixty only
Page 5 of 13
SAME AS IN ITEM
20gmTube
Anovate Cream
SAME AS IN ITEM
Employees' State Insurance Corporation
Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 142
Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020
lttem No I Drug Description
Firm Name Firm Rate/ unit Firm Packing Preference
1856 TRAMADOL AND PARACETAMOL TAB/ CAP - Each tab/cap to contain:Tramadol 37.50 mg, Paracetamol 325mg
PSYCHOTROPICS INDIA LIMITED
1.08/1 tab/ cap 10 tab FIRST
Rupees one paisa eight only
I Packing
Description of stores accepted
1 tab/ cap
Tromaml Extra
SAME AS IN ITEM
TROIKAA PHARMACEUTICALS LIMITED
1.4/1 tab/ cap 10 x 10 tab SECOND ZYROTRAM P RAPID
JOHNSON & JOHNSON PVT LTD
Rupees one paisa forty only
4.73/1 tab/ cap 15 tab THIRD
Rupees four paisa seventy three only
SAME AS IN ITEM
ULTRACET
SAME AS IN ITEM
1093 IBUPROFEN AND PCM ORAl SUSP • Each 5 ml to contain: 60ml bot Ibuprofen 100 mg., .F'aracetamol162.5 mg.
OVERSEAS HEALTH 10/60ml bot 60 ml bott CARE PVTLTD
PSYCHOTROPICS INDIA LIMITED
10.8/GOml bot
Rupees ten only
60mlbott
FIRST IBUTOP
SAME AS IN ITEM
SECOND lbupil Plus
SAME AS IN ITEM
Rupees ten paisa eighty only
Page 6 of13
Employees' State Insurance Corporation
Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 142
Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020
[ttemNo I Drug Description I Packing
Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted
1376 HYDROXY CHLOROQUINE TAB - Each tab to contain: Hydroxy 1 tab Chloroquine Sulfate 200mg
MICRO LABS LTD 2.33/1 tab 10 tab FIRST WIN FLAM SAME AS IN ITEM
Rupees two paisa thirty three only
OVERSEAS HEALTH CARE PVT LTD
3.5/1 tab 10 x 10 tab SECOND CARTIQUIN
WALLACE PHARMACEUTICALS PVTLTD
4.58/1 tab
Rupees three paisa fifty only
10tab THIRD
Rupees four paisa fifty eight only
11675 I ~RNOXICAM SR TAB- Each SR tab to contain: Lornoxicam 16
GLEN MARK 9.877/ltab 10 tab FIRST PHARMACEUTICALS LIMITED
Rupees nine paisa eight seven seven only
Page 7 of 13
SAME AS IN ITEM
OXCQ200
SAME AS IN ITEM
1 tab
FLEXILORSR
SAME AS IN ITEM
Employees' State Insurance Corporation
Rate Schedule of Running Rate Contract No. U-25/12/142./2017-Med V FOR RC 142
Valid from Thursday May 3'd 2018 to Saturday May 2nd 2020
lttemNo I Drug Description I Packing
Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted
j1862 I FEBUXOSTAT TAB- Each tab to contain: Febuxostat 40mg I 1 tab
Ajanta Pharma Ltd 1.145/1 tab 10 tab FIRST Feburic 40 SAME AS IN ITEM
Rupees one paisa one four five only
PSYCHOTROPICS INDIA LIMITED
1.74/1 tab 10tab SECOND Parustat-40
Rupees one paisa seventy four only
MICRO LABS LTD 2.02/1 tab 10tab THIRD
Rupees two paisa two only
SAME AS IN ITEM
XANURIX40 SAME AS IN ITEM
2024 PARACETAMOL 6SOMG TAB - Each Tab Paracetamol 650mg
to contains: 11 tab
MICRO LABS LTD 1,31/1 tab 1S tab FIRST DOLO 650 SAME AS IN ITEM
Rupees one paisa thirty one only
2082 Each tab to contain Dexketoprofen 25mg + Paracetamol 1 tab 325mg
Em cure Pharmaceuticals Limited
5.87/1 tab 10tab FIRST
Rupees five paisa eighty seven only
Page 8 of13
INFEN-P
SAME AS IN ITEM
Employees' State Insurance Corporation
Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 142
Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020
[ttem No l Drug Description
Firm Name Firm Rate/ unit Firm Packing Preference
2083 Aflibercept injection 40 mg I miAflibercept (r-DNA Origin) solution for intravitreal injection in ViaiEach pack contains: 1 vial and a 18 G Sterile filter needle 278 microliters/vial Each single dose vial provides a usable amount to deliver a single dose 50 microl.iters containing 2mg Aflibercept.
Bayer Zydus Pharma 40495/1 v1al 1 v1al and 18G sterile filter needle
FIRST Private Limited
l Packing
Description of stores accepted
1 vial
Eylea Mfg.: Bayer AG, Mullerstrasse,Berlin, Germany SAME AS IN ITEM
Rupees forty thousand four hundred ninety five only
~
1866 ANALGESIC CREAM - Each tube to contain: Methyl salicylate 30% w/w, Menthol 10 % w/w, Camphor 4 % w/w Excipients q.s.
Sanof1 lnd1a L1m1ted 53.99/.30 gm tube
30gm tube FIRST
Rupees fifty three paisa ninety nine only
30 gm tube
comb1flam MS Cream
SAME AS IN ITEM
1432 OLOPATADIN EYE DROP Each ml to contain: Olopatadin Sml vial l.Omg
Ajanta Pharma Ltd 15/Sml vial Sml
Rupees fifteen only
Cipla Ltd 39.8/Sml vial SML
FIRST Olopatadine Hydrochloride Opthalmic Solution USP 0.1 PER w/v SAME AS IN ITEM
SECOND IF2 EYE DROPS SAME AS IN ITEM
Rupees thirty nine paisa eighty only
Page 9 of13
Employees' State Insurance Corporation
Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 142
Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020
\ttemNo I Drug Description I Packing
Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted
1601 DORZOLAMIDE+TIMOLOL EVE DROP - Each vial to contain: Sml vial Dorzolamide 2% ,Timoloii.P. 0.5%
MICRO LABS LTD 114.24/Sml vial SML FIRST MISOPT EVE DROPS SAME AS IN ITEM
Cipla ltd
Rupees one hundred fourteen paisa twenty four only
190/Sml vial SML SECOND DOR20X T EVE DROPS SAME AS IN ITEM
Rupees one hundred ninety only
1923 CARBOXY METHYL CEL·l· Ul .. OSE EVE DROP - Each. ml to conta. in: 110m I vial Sodium Carboxy methyl cellulose Smg .
Cipla Ltd
MICRO LABS LTD
Ajanta Pharma Ltd
27.9/lOml vial 10ML FIRST ADD TEARS SAME AS IN ITEM
Rupees twenty seven paisa ninety only
29.12/lOml vial 10ML SECOND LUBhEX EYE DROPS SAME AS IN ITEM
Rupees twenty nine paisa twelve only
77/10ml vial 10 ml vial tHIRD
Rupees seventy seven only
AQUALUBE EYE DROP SAME AS IN ITEM
1924 DORZOLAMIDE EYE DROP - Each vial to contain: Dorzolamide Sml vial 2%
MICRO LABS LTD
Cipla Ltd
80.64/Sml vial SML FIRST MONOSOPT EYE DROPS SAME AS IN ITEM
Rupees eighty paisa Sixty four only
178/Sml vial SML SECOND DORZOX EVE DROPS SAME AS IN ITEM
Rupees one hundred seventy eight only
Page 10 of 13
Employees' State Insurance Corporation
Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 142
Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020
lttemNo I Drug Description I Packing
Firm Name Firm Rate/ unit Firm Packing Preference Description of stores
11228
Cipla Ltd
1598
I ACYCLOVIR EYE OINT- Each tube to contain: Acyclovir I.P.3%
19.5/5gm tube 5 gm tube FIRST
Rupees nineteen paisa fifty only
I
MOXIFLOXACIN + PREDNISOLONE EYE DROP - Each ml
contain: Moxifloxacin 0.5%, Prednisolone Acetate 1%,
Ajanta Pharma Ltd 18.54/Sml vial 5 ML VAIL FIRST
Rupees eighteen paisa fifty four only
accepted
I Sgm tube
ACIVIR EYE OINTMENT SAME AS IN ITEM
to Sml vial
Moxifloxacin Plus Prednisolone Acetate Opthalmic Solution SAME AS IN ITEM
1599 MOXIFLOXACIN EYE OINT - Each tube to contain: Moxifloxacin Sgm tube 0.5%
Cipla Ltd 3S/5gmtube 5gmtube
Rupees thirty five only
FIRST MOXICIP EYE OINTMENT SAME AS IN ITEM
1912 BESIFLOXACIN EYE DROP • Each ml to contain: Besifloxacin Sml bottle 0.6% (6mg/ml)
Ajanta Pharma Ltd 85.5/5ml bottle 5 ML vial FIRST BESIX EYE DROP SAME AS IN ITEM
Rupees eighty five paisa fifty only
Page 11 of13 --
I
Employees' St·ate Insurance Corporation
Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 142
Valid from Thursday May 3''d 2018 to Saturday May 2"d 2020
Lj l~re~m~N~o~ ______________ Lio~r~u~g~D~e=s=u~~~t~m~n~--------------~~~P~a=ck~m~g~ _________ :]
Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted
1602 TRAVOPROST EVE DROP- Each vial/ml to contain: Travoprost 2.5ml 0.004%
Ajanta Pharma Ltd 168.5/2.5ml 2.5 ml vial FIRST TOVAXO EVE DROP SAME AS IN ITEM
Cipla Ltd
ALCON
LABORATORIES {INDIA) PRIVATE
LIMITED
Rupees one hundred sixty eight paisa fifty only
269/2.5ml 2.5ML SECOND XOVATRA EYE DROPS SAME AS IN ITEM
Rupees two hundred sixty nine only
408.7/2.5ml 2.5ml THIRD
Rupees four hundred eight paisa seventy only
TRAVATAN Mfg.: S.A. Alcon Couvreur N. V.,
Belgium
SAME AS IN ITEM
I
1925 TRAVOPROST AND TIMOLOL EYE DROP - Each vial/ml to 2.5ml vial contain: Travoprost 0.004%, Timolol 0.5% J
Ajanta Pharma Ltd 172.80/2.5ml 2.5 ML VIAL FIRST TOVAXO T EVE DROP
ALCON
LABORATORIES
(INDIA) PRIVATE
LIMITED
vial SAME AS IN ITEM
Rupees one hundred seventy two paisa eighty only
550/2.5ml vial 2.5 miVial SECOND TRAVACOM Mfg.:
Rupees five hundred fifty only
Page 12 of13
S.A. Alcon Couvreur N.V.,
Belgium
SAME AS IN ITEM
Employees' State Insurance Corporation
Rate Schedule of Running Rate Contract No. U-25/12/:1.42/2017-Med V FOR RC 142
Valid from Thursday May 3'd 2018 to Saturday May 2nd 2020
[Item No I Drug Description I Packing
Firm Name Firm Rate/ unit Firm Packing Preference Description of stores
1211 ANTIBIOTIC EYE OINTMENT- Each gram to contain:Polymyxin B Sulphate 5000 IU Neomycin sulphate 3400 IU Zinc Bacitracin 400 IU Hydrocortisone 10 mg. in white sterilised petroleum jelly base.
GlaxoSmithKiine 33.17/5gm. Sgm Tube FIRST
Pharmaceuticals Ltd. Tube
Rupees thirty three paisa seventeen only
1251 POLYMIXIN, NEOMYCIN EYE OINT. - containing per gm. Polymixin B Sulphate 5000 IU Neomycin sulphate 3400 IU Zinc Bacitracin 400 IU
GlaxoSm1thKhne 24.35/5gm. SgmTube FIRST Pharmaceuticals Ltd. Tube
Rupees twenty four paisa thirty five only
1212 FLURBIPROFEN EYE DROPS - Containing: Flurbiprofen 0.03% w/v
MICRO LABS LTD 14.45/Sml. Vial SML FIRST
Rupees fourteen paisa forty five only
[1594 I EYE DROPS- Containing: Gatifloxacln Soln0.3%w/v
Ajanta Pharma Ltd 34.25/Sml vial 5 ML VIAL FIRST
Rupees thirty four paisa twenty five only
Page 13of13
accepted
Sgm. Tube
Neosporin H Omtment
SAME AS IN ITEM
Sgm. Tube
. . Neosporm Ant1b1ot1c
Ointment SAME AS IN ITEM
5ml. Vial
FBN EYE DROPS SAME AS IN ITEM
fsmlvial
GATE EYE DROPS SAME AS IN ITEM
Recommended